Package Leaflet: Information for the Patient
Pantoprazol Krka20mggastro-resistant EFG tablets
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Pantoprazol Krka contains the active substance pantoprazole. Pantoprazole is a selective inhibitor of the proton pump. Proton pump inhibitors like pantoprazole reduce the amount of acid in your stomach. It is used for the treatment of diseases related to stomach acid and intestine.
Pantoprazoleis used for:
Adultsand adolescents aged 12 years and older:
Adults:
Do not take Pantoprazol Krka:
Warnings and precautions
Talk to your doctor, pharmacist or nurse before you start taking Pantoprazol Krka
Tell your doctor immediatelyif you notice any of the following symptoms:
Your doctor will decide if you need any additional tests to rule out a malignant disease, as pantoprazole may alleviate the symptoms of cancer and could delay its diagnosis. If, despite treatment, your symptoms persist, additional tests will be performed.
If you take Pantoprazol Krka for a prolonged period (more than one year), your doctor may monitor you regularly. You should tell your doctor about any symptoms and/or new or unexpected events each time you visit your doctor.
Children and adolescents
The use of pantoprazole is not recommended in children, as it has not been tested in children under 12 years of age.
Other medicines and Pantoprazol Krka
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Pantoprazol Krkamay interfere with the effectiveness of other medicines, so tell your doctor if you are taking:
Talk to your doctor before taking pantoprazole if you need to have a specific urine test (for THC; Tetrahydrocannabinol).
Using Pantoprazol Krka with food and drinks
Take the tablets 1 hour before a meal without chewing or breaking them and swallow them whole with a little water.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
There is not enough data on the use of pantoprazole in pregnant women. It has been reported that pantoprazole is excreted in human breast milk. You should only use this medicine if your doctor considers that the benefit to you is greater than the potential risk to the fetus or baby.
Driving and using machines
Pantoprazol Krka has no or negligible influence on the ability to drive or use machines.
You should not drive or use machines if you experience side effects such as dizziness or blurred vision.
Pantoprazol Krkacontains sorbitol and sodium
This medicine contains 18 mg of sorbitol in each tablet
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is, essentially “sodium-free”.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, check with your doctor or pharmacist.
Method of administration
Take the tablets whole, without chewing or crushing, with a little water, 1 hour before a meal.
Unless your doctor has told you otherwise, the recommended doseis:
Adults and adolescents aged 12 years and older:
For the treatment of symptoms (e.g. heartburn, acid regurgitation, pain when swallowing) associated with gastroesophageal reflux disease
The recommended dose is one tablet per day. This dose usually provides relief within 2-4 weeks, or at most after another 4 weeks. Your doctor will tell you how long you need to take this medicine. Once this period is over, and if the symptoms come back, they can be controlled by taking one tablet per day.
For long-term treatment and prevention of relapses of reflux esophagitis
The recommended dose is one tablet per day. If the disease comes back, your doctor may double the dose, in which case you can take one 40 mg pantoprazole tablet per day instead. After healing, you can reduce the dose back to one 20 mg tablet per day.
Adults:
For the prevention ofgastroduodenalulcersin patients who need continuous treatment with NSAIDs
The recommended dose is one tablet per day.
Patient with liver problems
If you have severe liver problems, you should not take more than one 20 mg tablet per day.
Use in children and adolescents
Children under 12 years.
The use of these tablets is not recommended in children under 12 years of age.
If you take morePantoprazol Krkathan you should
Tell your doctor or pharmacist. There are no known symptoms of overdose.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to takePantoprazol Krka
Do not take a double dose to make up for a forgotten dose. Take your next dose as usual.
If you stop takingPantoprazol Krka
Do not stop taking these tablets without first talking to your doctor or pharmacist.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Stop using pantoprazole and seek immediate medical attention if you notice any of the following symptoms:
If you notice any of the following adverse effects, stop taking the tablets and inform your doctor immediately or contact the emergency service of the nearest hospital:
Severe allergic reactions (rare frequency(may affect up to 1 in 1000 people)):
Severe skin disorders (frequency not known(frequency cannot be estimated from available data)): you may notice one or more of the following:
Other severe disorders (frequency not known (frequency cannot be estimated from available data)):
Other adverse effects are:
Frequent(may affect up to 1 in 10 patients)
Infrequent(may affect up to 1 in 100 patients)
Rare(may affect up to 1 in 1,000 patients)
Very Rare(may affect up to 1 in 10,000 patients)
Frequency not known(frequency cannot be estimated from available data)
Adverse effects identified through blood tests:
Infrequent(may affect up to 1 in 100 patients)
Rare(may affect up to 1 in 1,000 patients)
Very Rare(may affect up to 1 in 10,000 patients)
Frequency not known(cannot be estimated from available data
Reporting of adverse effects
If you experience any type of adverse effects, consult your doctor or pharmacist, even if they are adverse effects that do not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the packaging after CAD.The expiration date is the last day of the month indicated.
Blister: store in the original packaging to protect it from moisture.
Bottle: keep it perfectly closed to protect it from moisture.
After opening the bottle for the first time, the product must be used within 3 months.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE point in your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. This way, you will help protect the environment.
Pantoprazol Krka Composition
Tablet core: mannitol, crospovidone (type A, type B), sodium carbonate, sorbitol (E420), calcium stearate.
Coating: hypromellose, povidone (K25), titanium dioxide (E171), yellow iron oxide (E172), propylene glycol, ethyl acrylate-methacrylic acid copolymer, sodium lauryl sulfate, polysorbate 80, macrogol 6000, and talc.
Appearance ofPantoprazol Krkaand Package Contents
Light brown-yellow, oval, and slightly biconvex tablets.
Package sizes
Blister pack of 7, 10, 14, 15, 28, 30, 56, 60, 84, 100, 100 x 1, 112, or 140 gastro-resistant tablets per box.
Plastic bottles of 250 gastro-resistant tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, D-27472 Cuxhaven, Germany
You can request more information about this medicine by contacting the local representative of the marketing authorization holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain
This medicine has been authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
Member State Name | Medicine Name |
Bulgaria | Pantoprazol Krka |
Lithuania | Pantoprazole Krka |
Greece | Pantoprazole TAD |
Cyprus | Pantoprazole TAD |
Malta | Panto TAD |
United Kingdom (Northern Ireland) | Pantoprazole |
France | Pantoprazole Krka |
Italy | Appryo |
Spain | Pantoprazol Krka |
Austria | Pantoprazol Alternova 20 mg gastro-resistant tablets |
Belgium | Pantoprazol Krka 20 mg |
Romania | Pantoprazol Krka |
Date of the last revision of this leaflet:October 2024
Detailed information about this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of PANTOPRAZOL KRKA 20 mg GASTRO-RESISTANT TABLETS in October, 2025 is around 8.74 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.